Robert J Kreitman Selected Research

Immunoglobulin Variable Region

11/2014	Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
4/2011	Renal excretion of recombinant immunotoxins containing pseudomonas exotoxin.
4/2009	A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
1/2009	Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.
12/2006	Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
10/2006	Immunotoxins in the treatment of hematologic malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert J Kreitman Research Topics

Disease

52	Hairy Cell Leukemia 12/2021 - 02/2002
46	Neoplasms (Cancer) 01/2021 - 02/2002
13	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2015 - 02/2002
12	Leukemia 01/2020 - 04/2002
11	Hematologic Neoplasms (Hematological Malignancy) 04/2014 - 02/2003
10	Residual Neoplasm 01/2022 - 05/2006
8	Hemolytic-Uremic Syndrome 10/2017 - 09/2005
6	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2009 - 02/2003
5	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 01/2016 - 04/2002
5	Mesothelioma 11/2014 - 08/2004
5	Lymphoma (Lymphomas) 10/2011 - 07/2002
4	COVID-19 01/2022 - 01/2021
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2017 - 03/2010
3	Disease Progression 01/2018 - 01/2012
3	Hypoalbuminemia 10/2017 - 09/2005
3	Malignant Mesothelioma 11/2014 - 08/2004
3	B-Cell Lymphoma (Lymphoma, B Cell) 05/2012 - 09/2011
3	Ovarian Neoplasms (Ovarian Cancer) 09/2005 - 08/2005
2	Infections 06/2021 - 06/2009
2	Thrombocytopenia (Thrombopenia) 10/2020 - 09/2011
2	Capillary Leak Syndrome 01/2020 - 10/2017
2	Splenomegaly 03/2018 - 06/2009
2	Thrombotic Microangiopathies 10/2017 - 09/2014
2	T-Cell Leukemia (Leukemia, T Cell) 08/2012 - 04/2002
2	Fatigue 05/2012 - 09/2005
2	Edema (Dropsy) 05/2012 - 09/2005
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 05/2012 - 01/2010
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 03/2010 - 10/2006
2	Pancreatic Neoplasms (Pancreatic Cancer) 08/2009 - 09/2007
2	Hodgkin Disease (Hodgkin's Disease) 01/2009 - 07/2002
2	Carcinoma (Carcinomatosis) 05/2007 - 09/2005
2	Neoplasm Metastasis (Metastasis) 09/2005 - 08/2005
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2004 - 05/2002
2	Diphtheria 01/2004 - 05/2002
1	Cytopenia 06/2021
1	Lymphadenopathy 10/2020
1	Hemorrhage 10/2020
1	Pancytopenia 03/2018
1	Anaplastic Thyroid Carcinoma 01/2018

Drug/Important Bio-Agent (IBA)

50	Immunotoxins (Immunotoxin)IBA 01/2020 - 02/2002
19	ExotoxinsIBA 06/2015 - 04/2002
18	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2002
17	purineIBA 01/2022 - 02/2005
13	immunotoxin HA22IBA 11/2021 - 02/2009
11	Rituximab (Mabthera)FDA Link 01/2022 - 07/2002
11	Cladribine FDA LinkGeneric 12/2021 - 05/2006
10	AntigensIBA 11/2014 - 10/2006
9	Pharmaceutical PreparationsIBA 12/2018 - 07/2002
9	B3(Fv)-PE38KDEL recombinant immunotoxinIBA 01/2016 - 02/2002
7	MesothelinIBA 11/2014 - 08/2005
7	Monoclonal AntibodiesIBA 04/2014 - 04/2002
7	Diphtheria ToxinIBA 01/2009 - 05/2002
6	AntibodiesIBA 01/2016 - 04/2002
6	Immunoglobulin Variable RegionIBA 11/2014 - 10/2006
5	RFB4(dsFv)-PE38 recombinant immunotoxinIBA 10/2011 - 01/2005
5	denileukin diftitox (Ontak)FDA Link 01/2009 - 02/2003
5	LigandsIBA 01/2009 - 07/2004
4	Pentostatin (Nipent)FDA LinkGeneric 06/2021 - 10/2009
4	Immunoconjugates (Immunoconjugate)IBA 12/2015 - 10/2011
4	Antineoplastic Agents (Antineoplastics)IBA 06/2014 - 10/2003
4	Bacterial ToxinsIBA 10/2013 - 02/2003
4	Interleukin-2 (IL2)IBA 01/2009 - 07/2004
4	Interleukin-4 (Interleukin 4)IBA 09/2005 - 10/2003
3	Agammaglobulinaemia Tyrosine KinaseIBA 01/2021 - 01/2020
3	CreatinineIBA 01/2020 - 05/2012
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020 - 02/2015
3	Transaminases (Aminotransferases)IBA 10/2017 - 09/2005
3	Peptides (Polypeptides)IBA 10/2007 - 01/2004
3	Cytotoxins (Cytolysins)IBA 09/2005 - 07/2002
3	Interleukin-4 Receptors (Interleukin 4 Receptor)IBA 09/2005 - 08/2004
2	InterferonsIBA 01/2022 - 10/2006
2	Antiviral Agents (Antivirals)IBA 01/2022 - 07/2021
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 11/2014
2	Tartrate-Resistant Acid PhosphataseIBA 01/2020 - 03/2018
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2016 - 10/2013
2	Differentiation AntigensIBA 06/2015 - 04/2014
2	Alemtuzumab (Campath)FDA Link 12/2013 - 07/2002
2	Bendamustine Hydrochloride FDA Link 11/2013 - 06/2011
2	B-Lymphocyte Epitopes (B-Cell Epitope)IBA 04/2011 - 12/2006
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2009 - 05/2002
2	Interleukin-3 (Interleukin 3)IBA 01/2009 - 01/2004
2	Surface Antigens (Surface Antigen)IBA 01/2007 - 01/2006
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2006 - 02/2003
2	Amino Acids FDA Link 01/2004 - 04/2002
1	Purine NucleosidesIBA 06/2021
1	VemurafenibIBA 06/2021
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2021
1	ibrutinibIBA 01/2021
1	AnnexinsIBA 01/2020
1	Annexin A1IBA 03/2018
1	dabrafenibIBA 01/2018
1	trametinibIBA 01/2018
1	Dexamethasone (Maxidex)FDA LinkGeneric 10/2017

Therapy/Procedure

30	Therapeutics 10/2020 - 04/2002
19	Drug Therapy (Chemotherapy) 01/2022 - 05/2002
3	Splenectomy 10/2020 - 10/2006
3	Immunotherapy 02/2009 - 01/2005
2	Complementary Therapies (Alternative Medicine) 12/2018 - 12/2015
2	Plasmapheresis 06/2009 - 09/2005
1	Platelet Transfusion (Blood Platelet Transfusions) 10/2020